Single gene (RASSF1A) methylated tumor markers predict bladder tumor recurrence after urothelial carcinoma surgery: a prospective cohort study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044366

Enrollment

Unknown

Registered

2021-03-17

Start date

2021-03-22

Completion date

Unknown

Last updated

2021-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urothelial carcinoma

Interventions

Gold Standard:Pathological diagnosis

Index test:RASSF1A&#32

gene&#32

methylation&#32

marker.

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Clinical considerations for the diagnosis of patients with urothelial carcinoma (UC); 2. Surgical treatment is planned; 3. Patients with current UC clinical stage can meet R0 resection criteria; 4. The postoperative pathology is urothelial carcinoma; 5. Patients sign the informed consent forms.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to surgery or unwillingness to surgical treatment; 2. Urothelial carcinoma is excluded from postoperative pathology; 3. The current clinical stage of UC requires neoadjuvant chemotherapy before surgery; 4. The patient also has other urological malignancies.

Design outcomes

Primary

Measure	Time frame
RASSF1A gene methylation status;Bladder tumor recurrence;	—

Secondary

Measure	Time frame
Cancer specific survival;Overall survival;	—

Countries

China

Contacts

Public ContactGengyan Xiong

Peking University First Hospital

xgy13537221@163.com+86 13011111205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026